Рет қаралды 39,495
Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are two drugs for multiple sclerosis which both work on b-cells. In this video, I explain differences between the two drugs and results from clinical trials. Which drug has fewer drug-reactions? Which has a lower rate of serious infections? Is Kesimpta more optimally dosed?
Sources:
Subgroup analysis of OPERA trials: www.ncbi.nlm.nih.gov/pmc/arti...
OPERA trials: www.nejm.org/doi/full/10.1056...
NEJM article summarizing the ASCLEPIOS trials: www.nejm.org/doi/10.1056/NEJM...
Comment or ask questions below! I would be happy to answer!
Subscribe on KZbin for more videos every Wednesday!
Make video requests in the comments section!
My book "Resilience in the Face of Multiple Sclerosis" on Amazon: www.amazon.com/dp/B07WP7H5LK
Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system. He is a partner in the Southern California Permanente Medical Group and practices in Downey, California (South Los Angeles). He has several publications on MS epidemiology and has participated in clinical trials for MS therapeutics. You can follow him on twitter @Brandon_Beaber where he regularly posts about MS news and research.
Follow me on twitter: / brandon_beaber
Music: INNER GRACE - Copyright 2018 Wilton Vought
Source: Really Really Free Music
Link: • Video
The video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.